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Abstract
Background: Chronic kidney disease (CKD) is associated to a higher stroke risk. Anemia is a common consequence
of CKD, and is also a possible risk factor for cerebrovascular diseases. The purpose of this study was to examine if
anemia and CKD are independent risk factors for mortality after stroke.
Methods: This historic cohort study was based on a stroke registry and included patients treated for a first clinical
stroke in the stroke unit of one academic hospital over a three-year period. Mortality predictors comprised
demographic characteristics, CKD, glomerular filtration rate (GFR), anemia and other stroke risk factors. GFR was
estimated by means of the simplified Modification of Diet in Renal Disease formula. Renal function was assessed
according to the Kidney Disease Outcomes Quality Initiative (K/DOQI)-CKD classification in five groups. A value of
hemoglobin < 120 g/L in women and < 130 g/L in men on admission defined anemia. Kaplan-Meier survival
curves and Cox models were used to describe and analyze one-year survival.
Results: Among 890 adult stroke patients, the mean (Standard Deviation) calculated GFR was 64.3 (17.8) ml/min/
1.73 m
2 and 17% had anemia. Eighty-two (10%) patients died during the first year after discharge. Among those,
50 (61%) had K/DOQI CKD stages 3 to 5 and 32 (39%) stages 1 or 2 (p < 0.001). Anemia was associated with an
increased risk of death one year after discharge (p < 0.001). After adjustment for other factors, a higher
hemoglobin level was independently associated with decreased mortality one year after discharge [hazard ratio
(95% CI) 0.98 (0.97-1.00)].
Conclusions: Both CKD and anemia are frequent among stroke patients and are potential risk factors for
decreased one-year survival. The inclusion of patients with a first-ever clinical stroke only and the determination of
anemia based on one single measure, on admission, constitute limitations to the external validity. We should
investigate if an early detection and management of both CKD and anemia could improve survival in stroke
patients.
Introduction
Stroke is an increasing cause of mortality and severe
neurological disability, including late-life dementia,
worldwide [1-3]. Chronic kidney disease (CKD) is an
independent risk factor for cerebrovascular diseases
[4,5]. Anemia, a frequent feature of reduced kidney
function, could actually play a role in the relationship
between CKD and stroke [6]. However, the relationship
between CKD-, anemia- and stroke-related outcomes
needs to be studied further. Chronic kidney disease
(CKD) is also an increasing public health problem
worldwide, associated with poor outcomes and high cost
[7]. A loss of renal function is associated with an ele-
vated risk of stroke and cardiovascular diseases com-
pared to the general population [8-10]. Other risk
factors for stroke are commonly encountered in dialysis
patients [11]. * Correspondence: Bernard.Burnand@chuv.ch
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and independent predictor of survival after a stroke [12],
while another study indicated that this association was
related to the presence of anemia [6]. When anemia was
present with chronic kidney disease, the risk of stroke
increased clearly compared to patients with CKD with-
out anemia, in which the risk of stroke was only moder-
ately increased. Among those patients with anemia and
low creatinine clearance the crude stroke rate per 1000
person-years was 10.53 and, among those without ane-
mia and low creatinine clearance, the rate was 2.85 [6].
To further study the role of CKD and anemia on out-
come in stroke patients, the objective of this study was
to examine the association between chronic kidney dis-
ease and anemia with in-hospital mortality and one-year
survival among hospitalized stroke patients.
Patients and Methods
Setting, patients
In this retrospective cohort study, all consecutive
patients hospitalized with a diagnosis of a first ever clin-
ical stroke, and recorded in the Stroke Registry of the
Neurology Service of an academic medical center in
Western Switzerland, were included [13]. All patients
discharged from the hospital after a hemorrhagic or
ischemic stroke between 1
st January 2001 and 31
st
December 2003 were considered for inclusion in a retro-
spective cohort study. We excluded patients who could
not be reached at follow-up, especially those living
abroad, refusals and cases with missing values for creati-
nine or hemoglobin, as well as subjects with incomplete
coded discharge information.
Data collection
Unless otherwise indicated, all information was retrieved
from the Hospital Stroke Registry. This Stroke Registry
was limited to patients with a first ever clinical stroke
admitted to the Centre Hospitalier Universitaire Vaudois
since 1979 [13]. With the exception of one-year survival,
all information was collected during the index hospitali-
zation for a first ever clinical stroke. Information on
demographic characteristics and risk factors for stroke
(i.e. hypertension, hypercholesterolemia, diabetes, and
smoking habits (ex-, current or non-smoker)) were col-
lected from the Stroke Registry. Other variables included
the presence of ischemic heart disease and atrial fibrilla-
tion, peripheral arterial insufficiency (defined according
to the clinical definition of claudication classified by
Fontaine), a positive family history for stroke and/or
heart disease and transient ischemic attack (TIA: a neu-
rological disorder due to a temporary ischemia of the
brain which lasts less than 24 hours). This information
was prospectively asked to the patients or their family
members at admission to the hospital and added to the
stroke registry. Diabetes was considered present if fast-
ing plasma glucose was >7.0 mmol/l, a 2-hour value in
the oral glucose tolerance test or a random plasma glu-
cose concentration >11.1 mmol/l, in the presence of
symptoms [14]. Dyslipidemia was retained if LDL was
>2.6 mmol/l, or if, in absence of a LDL value, total cho-
lesterol was >5 mmol/l [15]. Patients with already trea-
ted diabetes and hypercholesterolemia were also
registered. The presence of Ischemic heart disease was
categorized as follows: none; Ischemic Heart disease
(regrouping angina without heart attack and heart
attack), and heart failure.
An evaluation of the functional status was also col-
lected from the Registry. The functional status is a dis-
ability scale that represents the activities of daily living in
a five-level scale with Stage I representing no disability,
Stage II mild disability (return to all activities, although
with difficulty), Stage III moderate disability (return to
main activities, although with difficulty), Stage IV severe
disability (impossible to return to most activities) and
Stage V death. We did not use the widely used modified
Rankin Scale (mRS) because our five-level scale was used
s i n c et h ec r e a t i o no ft h eL a u s a n n eS t r o k eR e g i s t r y( L S R )
in 1978. At this time, the mRS had not yet been defined.
In comparison, Stage I (LSR) corresponds to Stage 0-I
(mRS), Stage II to Stage II, Stage III to Stage III-IV, Stage
IV to Stage V and Stage V to Stage VI. The serum creati-
nine, hemoglobin and hematocrit values were collected
from the electronic files of the hospital’s laboratory. The
first hemoglobin and serum creatinine values of the hos-
pitalization were used for each patient. Anemia was
defined as a hemoglobin level <120 g/L in women and
<130 g/L men according to the World Health Organiza-
tion (WHO) definition [16]. We estimated the Glomeru-
lar Filtration Rate (GFR) by means of the simplified
Modification of Diet in Renal Disease formula [17,18].
Renal function was assessed according to the Kidney Dis-
ease Outcomes Quality Initiative (K/DOQI)-CKD classifi-
cation in five groups [17]. Stage I corresponded to
patients with GFR values ≥90 ml/min/1.73 m
2, Stage II to
G F Rv a l u e sf r o m6 0t o8 9m l / m i n / 1 . 7 3m
2,S t a g eI I I
to GFR values from 30 to 59 ml/min/1.73 m
2, Stage IV to
G F Rv a l u e sf r o m1 5t o2 9m l / m i n / 1 . 7 3m
2,a n dS t a g eV
to GFR values <15 ml/min/1.73 m
2.T h eS t r o k eR e g i s t r y
number allowed us to access to the medical chart for
each stroke patient hospitalized between 2001 and 2003,
featuring all necessary information about the patients,
such as interventions, reports of admission notes and
medical consultations and discharge letters, discharge
status including death, and discharge diagnoses (Interna-
tional Classification of Diseases 10
th Revision (ICD-10)).
The Charlson comorbidity index, a weighted average of
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administrative data, using an algorithm that was recently
developed for ICD-10 codes [19].
Main outcome measures
The outcomes of interest were in-hospital mortality and
one-year survival in hospitalized stroke patients. Follow-
up information to establish survival after discharge from
hospital was collected via telephone interviews with the
patients, their relatives, their physicians, and/or the nur-
sing homes. For a few patients, this information was
obtained from Population Registries. The one-year mor-
tality rate was calculated from the date of discharge
from hospital.
Statistical analyses
Bivariate analyses, including chi-square tests, Fisher’s
exact tests, Student T-tests or ANOVA methods, where
appropriate, were used in a first step. Kaplan-Meier
(KM) survival curves were obtained using the log rank
test to assess if KM survival curves for patients with or
without CKD or with different levels of hemoglobin
were statistically different. For these survival curves, the
follow-up was extended up to over five years, to a maxi-
mum of 1889 days. A univariate survival analysis was
performed, using hemoglobin and GFR as continuous
variables (Cox proportional hazard analysis).
We then conducted multivariate analyses adjusted for
potential confounding factors. Cox models were used to
assess one-year survival and to calculate adjusted hazard
ratios with their associated 95% confidence intervals [20].
We checked the proportional hazard assumption. Our
modeling strategy was based on a priori consideration of
bivariate analyses’ results and clinical judgment to select
the more important variables. We applied the Mickey
and Greenland method to select the final model, using a
step-forward regression method with a p-value for entry
of 0.20 [21]. Variables included in the first model were
hemoglobin, GFR, age, gender, hypertension, diabetes,
past and current smokers (reference = non smokers),
hypercholesterolemia, heart failure, ischemic heart dis-
ease, peripheral arterial insufficiency, atrial fibrillation,
TIA before the stroke attack, functional status in four
categories (reference = functional status I), and the Charl-
son comorbidity index in four categories (reference =
Charlson score 0 or 1). A significance level of 0.05 was
used in all statistical analyses done in this study. All ana-
lyses were performed with the SAS Software, version 9.1
(SAS Institute, Cary, NC, USA).
The collection and use of the data was authorised by
the Federal Data Protection and Information Commis-
sioner within the framework of the Data Protection
Law. Every included patient gave informed consent.
Results
Baseline Characteristics
A total of 963 eligible patients aged 16 to 97 were consid-
ered. We excluded two patients who had a transient
ischemic attack and not a stroke, and three patients who
had already had a previous symptomatic stroke. In addi-
tion, 10 subjects who could not be reached by phone, five
who denied participation and 20 patients living abroad
were excluded, as well as 16 with missing laboratory
values for creatinine or hemoglobin, 10 discharged in
2004, and seven because of missing ICD-10 diagnostic
codes. Among the 890 patients included, the mean (stan-
dard deviation: SD) age was 69.0 (15.7) years (25
th to 75
th
interquartile range 59-80); 54% were men. A history of
hypertension was present in 59% of patients, 15% had
diabetes, 39% hypercholesterolemia, and 22% were cur-
rent smokers. A history of cardiovascular disease was
reported by 41% of the patients, a family history of stroke
or coronary artery disease by 2%, migraine by 2%, TIA
before stroke by 9%, and peripheral arterial insufficiency
by 4% (Table 1, columns 1 and 2). The mean (SD) Charl-
son comorbidity index was 2.8 (1.6).
Prevalence of CKD
The mean (SD) serum creatinine value was 102.7 (43.3)
μmol/L (25
th to 75
th interquartile range: 83 to 109
μmol/L). The mean (SD) calculated GFR was 64.3 (17.8)
ml/min/1.73 m
2 (25
th to 75
th interquartile range: 53.7 to
76.2 ml/min/1.73 m
2). The distribution of renal impair-
ment according to K/DOQI CKD stages among the
entire cohort showed that 59 (7%), 469 (53%), 335
(38%), 21 (2%) and 6 (1%) of the patients had Stages I
to V GFR respectively. The mean GFR was statistically
lower in elderly patients, in women, in patients with
hypertension, diabetes, a history of heart diseases, heart
failure, and a family history for stroke (Table 2).
Prevalence of Anemia
The mean (SD) hemoglobin at admission was 139 (18) g/L
(25
th to 75
th interquartile range 129-152 g/L). Hemoglobin
<140 g/L was found in 53% of the patients, 35% had
hemoglobin between 120 g/L and 140 g/L and 12% <120
g/L. Anemia was present in 148 patients (17%). Figure 1
depicts the frequencies of stroke patients by categories of
hemoglobin, according to K/DOQI CKD stages. Among
patients with hemoglobin <120 g/L, a lower proportion of
K/DOQI CKD Stages I or II was observed compared to
patients with hemoglobin >140 g/L (Table 3). The mean
GFR was progressively lower with an increasing severity of
anemia (Table 3) across the three hemoglobin categories.
Anemia was present in 67 patients (45%) with K/DOQI
CKD Stages I or II and 81 (55%) with K/DOQI CKD
Stages III to V (p < 0.0001).
Del Fabbro et al. BMC Nephrology 2010, 11:27
http://www.biomedcentral.com/1471-2369/11/27
Page 3 of 10Table 1 Hospital and One-Year Mortality Related to Patients Characteristics and Risk Factors for Stroke, CHUV, 2001-
2003, N = 890 on admission and N = 857 at one year
Characteristic and risk factors for stroke Number (%)
N (%)
Hospital
mortality
N (%)
P value One-Year
mortality
N (%)
P value
N (%) 33 (3.7) 82 (9.6)
Age <0.001 <0.001
<60 years 240 (27.0) 2 (6.1) 6 (7.3)
60-70 years 151 (17.0) 1 (3.0) 6 (7.3)
71-80 years 267 (30.0) 11 (33.3) 26 (31.7)
<80 years 232 (26.0) 19 (57.6) 44 (53.7)
Gender 0.21 0.20
Male 479 (53.8) 14 (42.4) 39 (47.6)
Female 411 (46.2) 19 (57.6) 43 (52.4)
Risk Factors for Stroke
Hypertension 528 (59.3) 19 (57.6) 0.86 49 (59.8) 1.00
Diabetes 133 (15.0) 3 (9.1) 0.46 17 (20.7) 0.15
Hypercholesterolemia 346 (38.9) 6 (18.2) 0.02 19 (23.2) 0.001
Smoking 0.009 0.002
No 595 (66.8) 30 (90.9) 67 (81.7)
Yes 198 (22.2) 3 (9.1) 6 (7.3)
Ex-smoker 97 (11.0) 0 9 (11.0)
Antecedent
Ischemic Heart Disease 126 (14.2) 7 (21.2) 0.30 15 (18.3) 0.24
Heart failure 97 (11.0) 8 (24.2) 0.02 20 (24.4) <0.001
Peripheral Arterial Insufficiency 36 (4.0) 0 0.64 9 (11.0) 0.005
Atrial Fibrillation 125 (14.0) 9 (27.3) 0.04 16 (19.5) 0.12
Positive Family History for Stroke/Heart Disease 16 (1.8) 0 1.00 0 0.34
TIA Before Stroke 77 (8.7) 2 (6.1) 1.00 2 (2.4) 0.04
Severity of disease
Functional Status <0.001 <0.001
I 263 (29.6) 0 6 (7.3)
II 201 (22.6) 0 10 (8.2)
III 164 (18.4) 0 13 (15.9)
IV 230 (25.8) 1 (3.0) 53 (64.6)
Death 32 (3.6) 32 (97.0)
Charlson Comorbidty Index 0.62 <0.001
Charlson score 0 or 1 268 (30.1) 7 (21.2) 11 (13.4)
Charlson score 2 93 (10.5) 3 (9.1) 9 (11.0)
Charlson score 3 298 (33.5) 12 (36.4) 24 (29.3)
Charlson score ≥4 231 (26.0) 11 (33.3) 38 (46.3)
Chronic Kidney Disease
Stage 1 (GFR ≥90) 59 (6.3) 0 0.052 5 (6.1) <0.001
Stage 2 (GFR: 60-89) 469 (52.7) 13 (39.4) 27 (32.9)
Stage 3 (GFR: 30-59) 335 (37.6) 18 (54.6) 43 (52.4)
Stage 4 or 5 (GFR ≤29) 27 (3.0) 2 (6.1) 7 (8.5)
Mean (SD) GFR ml/min/1.73 m
2 64.3 (17.8) 55.2 (12.6) <0.001 55.6 (20.6) <0.001
TIA: Transient Ischemic Attack.
GFR: Glomerular Filtration Rate ml/min/1.73 m
2.
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Thirty-three (3.7%) patients died during their hospitali-
zation. Among them, 20 (61%) had K/DOQI CKD
Stages III to V and 13 (39%) Stages I or II (p = 0.052),
and their mean GFR was 55.2 ml/min/1.73 m
2.E i g h t y -
two (10%) patients died during the first year of follow-
up. Among them 50 (61%) had K/DOQI CKD Stages III
to V and 32 (39%) Stages I or II (p < 0.0001), and their
mean GFR was 55.6 ml/min/1.73 m
2. Indeed, the pre-
sence of an increasing stage of CKD was associated with
an increased risk of death during the hospitalization and
the first year after discharge (Table 1). Anemia was also
associated with an increased risk of death (Table 3).
Proportions of in-hospital and one-year mortality
increased progressively, with an increasing degree of
anemia expressed in the three hemoglobin categories
Table 2 Chronic Kidney Disease Prevalence and Mean Glomerular Filtration Rate according to Patients Characteristics
and Risk Factors for Stroke, CHUV, 2001-2003, N = 890
Characteristic and risk factors for stroke Number
N (%)
Chronic Kidney Disease
N (%)
P value Mean (SD)
GFR
ml/min/1.73 m2
P value
I II III IV-V
N (%) 890 (100.0) 59 (6.6) 469 (52.7) 335 (37.6) 27 (3.0) 64.3 (17.8)
Age <0.001 <0.001
≤60 years 240 (27.0) 39 (16.3) 177 (73.8) 20 (8.3) 4 (1.7) 76.8 (16.5)
60-70 years 151 (17.0) 10 (6.6) 92 (60.9) 47 (31.1) 2 (1.3) 67.4 (16.2)
71-80 years 267 (30.0) 8 (3.0) 121 (45.3) 127 (47.6) 11 (4.1) 59.1 (15.8)
<80 years 232 (26.0) 2 (0.86) 79 (34) 141 (61) 10 (4.3) 55.2 (13.9)
Gender <0.001 <0.001
Male 479 (53.8) 52 (10.9) 287 (59.9) 126 (26.3) 14 (2.9) 69.1 (18.7)
Female 411 (46.2) 7 (1.7) 182 (44.3) 209 (50.9) 13 (3.2) 58.6 (14.8)
Risk Factors for stroke
Hypertension 528 (59.3) 22 (4.2) 246 (46.6) 239 (45.3) 21 (3.9) <0.001 60.3 (16.9) <0.001
Diabetes 133 (15.0) 11 (8.3) 51 (38.3) 64 (48.1) 7 (5.3) 0.003 59.6 (19.7) 0.003
Hyper-Cholesterolemia 346 (38.9) 20 (5.8) 181 (52.3) 135 (39) 10 (2.9) 0.812 63.7 (17.0) 0.47
Smoking <0.001 <0.001
No 595 (66.8) 24 (4.03) 285 (48) 268 (45.04) 18 (3.03) 61.1 (16.2)
Yes 198 (22.2) 30 (15.15) 127 (64.1) 37 (18.7) 4 (2.02) 73.7 (18.0)
Ex-smoker 97 (11.0) 5 (5.15) 57 (58.8) 30 (31) 5 (5.15) 64.7 (19.8)
Antecedent
Ischemic Heart Disease 126 (14.2) 3 (2.4) 55 (43.7) 62 (49.2) 6 (4.8) 0.005 59.2 (16.1) <0.001
Heart failure 97 (11.0) 3 (3.1) 35 (36.1) 54 (55.7) 5 (5.2) 0.0003 55.4 (17.6) <0.001
Peripheral Arterial Insufficiency 36 (4.0) 2 (5.6) 18 (50) 14 (38.9) 2 (5.6) 0.703 62.4 (21.4) 0.52
Atrial Fibrillation 125 (14.0) 4 (3.2) 51 (40.8) 64 (51.2) 6 (4.8) 0.0017 57.0 (16.8) <0.001
Positive Family History for Stroke/
Heart Disease
16 (1.8) 4 (25) 11 (68.8) 1 (6.25) 0 0.005 79.5 (15.0) <0.001
TIA before Stroke 77 (8.7) 5 (6.5) 39 (50.7) 31 (40.3) 2 (2.6) 0.964 62.0 (17.3) 0.25
Severity of disease
Functional Status 0.006 0.04
I 263 (29.6) 11(4.2) 157 (59.7) 92 (35) 3 (1.14) 65.3 (15.6)
II 201 (22.6) 20 (9.9) 104 (51.7) 71 (35.3) 6 (3) 65.2 (17.8)
III 164 (18.4) 10 (6.1) 91 (55.5) 54 (33) 9 (5.5) 65.1 (19.3)
IV 230 (25.8) 18 (7.8) 104 (45.2) 100 (43.5) 8 (3.5) 62.7 (19.4)
Death 32 (3.6) 0 13 (40.6) 18 (56.3) 1 (3.13) 56.2 (11.6)
Charlson score <0.001 <0.001
Charlson score 0 or 1 268 (30.1) 18 (6.7) 174 (65) 74 (27.6) 2 (0.8) 68.8 (16.2)
Charlson score 2 93 (10.5) 2 (2.2) 47 (50.5) 42 (45.2) 2 (2.2) 62.2 (14.4)
Charlson score 3 298 (33.5) 23 (7.7) 156 (52.4) 111 (37.3) 8 (2.7) 64.7 (17.4)
Charlson score ≥4 231 (26.0) 16 (6.9) 92 (39.8) 108 (46.8) 15 (6.5) 59.2 (19.9)
TIA: Transient Ischemic Attack.
GFR: Glomerular Filtration Rate ml/min/1.73 m
2.
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K/DOQI CKD Stages III and IV (Figure 2) and lower
hemoglobin (Figure 3) were risk factors for decreased
survival, log rank test p < 0.001 and p < 0.001,
respectively. In univariate survival analysis, both hemo-
globin and GFR were positively associated with survival,
as indicated by hazard ratios of 0.976 (95% CI 0.966-
0.986) and 0.970 (95% CI 0.959-0.982), respectively.
Figure 1 Frequencies of Patients Hospitalised for a First Stroke, by Hemoglobin Level (< 120, 120-140, > 140 g/l), according to K/
DOQI CKD Stage.
Table 3 Hemoglobin Levels Related to CKD, GFR and Mortality in Patients Hospitalized for a First Stroke, CHUV, 2001-
2003, N = 890
Hemoglobin in g/L
N (%) <120 g/L N (%)
or Mean (SD)
120-140 g/L N (%)
or Mean (SD)
>140 g/L N (%)
or Mean (SD)
Total (%) P Value
N = 890 108 (12.1) 315 (35.4) 467 (52.5) 890 (100)
Gender <0.001
Male 42 (38.9) 123 (39.1) 314 (67.2) 479 (53.8)
Female 66 (61.1) 192 (60.1) 153 (32.8) 411 (46.2)
Age <0.001
≤60 years 20 (18.5) 60 (19.1) 160 (34.3) 240 (27.0)
60-70 years 14 (13.0) 44 (14.0) 93 (19.9) 151 (17.0)
71-80 years 31 (28.7) 102 (32.4) 134 (28.7) 267 (30.0)
<80 years 43 (39.8) 109 (34.6) 80 (17.1) 232 (26.0)
Mean (SD) Hemoglobin 10.7 (12.7) 13.1 (5.4) 15.2 (10.1) 13.9 (1.8) <0.001
CKD
Stage 1 (GFR ≥90) 7 (6.5) 18 (5.7) 34 (7.3) 59 (6.6) <0.001
Stage 2 (GFR: 60-89) 40 (37.0)50 (46.3) 149 (47.3) 280 (60.0) 469 (52.7)
Stage 3 (GFR: 30-59) 11 (10.2) 140 (44.4) 145 (31.1) 335 (37.6)
Stage 4/5 (GFR ≤29) 8 (2.5) 8 (1.7) 27 (3.0)
Mean (SD) GFR ml/min/1.73 m
2 56.7 (21.6) 62.6 (16.8) 67.2 (16.8) 64.3 (17.8) <0.001
In-hospital mortality (N = 890) 6 (5.6) 14 (4.4) 13 (2.8) 33 (3.7) 0.27
One-year mortality (N = 857) 23 (22.6) 30 (10.0) 29 (6.4) 82 (9.6) <0.001
GFR: Glomerular Filtration Rate ml/min/1.73 m
2.
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Page 6 of 10Figure 2 Kaplan-Meier Survival Curve According to K/DOQI CKD Stage, among Patients Hospitalized for a First Stroke, N = 856 [GFR
(ml/min/1.73 m
2) ≥90: 59; GFR 60-89: 456; GFR: 30-59: 316; GFR ≤29: 25)].
Figure 3 Kaplan-Meier Survival Curve for Individuals with Hemoglobin Levels of < 120 (102), 120-140 (300) and > 140 (454) g/L,
among Patients Hospitalized for a First Stroke, N = 856.
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Cox models were used to assess the determinants of
survival at one year. Hemoglobin was independently
associated with survival at one-year (Table 4) controlling
for age, glomerular filtration rate, hypertension,
hypercholesterolemia, previous TIA, functional status
and Charlson comorbidity index. For each 10 g/L
increase in hemoglobin, the annual subsequent probabil-
ity of death declined by 1.6%. GFR was not statistically
associated with survival in the model. The latter relation
was not statistically significant, however. The interaction
term between hemoglobin and GFR was also not signifi-
cantly associated with survival.
Discussion
We observed that anemia and chronic kidney disease are
two frequent conditions among stroke patients. Anemia
was independently associated with a decreased one-year
survival. Although GFR was associated with mortality in
bivariate analyses, this relationship was not statistically
significant in multivariate analyses. These associations
between reduced kidney function and anemia and the
risk of death among stroke patients have not been
reported previously.
So far, most studies have concentrated on the risk of
death among heart failure and myocardial infarction
patients with CKD and anemia [22-24]. Previous studies
already showed that CKD [25,26] and anemia [27,28]
increase the risk of death among patients with coronary
heart disease, heart failure and ischemic heart disease.
In this study we wanted to assess if we observed similar
findings for stroke patients. Previous studies have shown
that an elevated serum creatinine concentration is asso-
ciated with an increased risk of stroke and that CKD
and anemia are risk factors for stroke [6,29]. Indeed,
41% of our stroke study patients were in K/DOQI CKD
stages III to V and 17% had anemia.
Our study findings were similar to those obtained by
Friedman, in which serum creatinine was found to be a
strong and independent predictor of survival after stroke
in the elderly [12]. In our study, elevated serum creati-
nine was associated with increased hospital mortality
and decreased one-year survival.
Anemia is common among individuals with reduced
kidney function, generally because of a decreased pro-
duction of erythropoietin [25-31]. It is a consequence of
chronic kidney disease and it also worsens the progres-
sion of renal insufficiency. Anemia increases the preva-
lence of CKD with decreasing creatinine clearance
[32,33]. In our study, the mean GFR was lower in
patients with anemia and more patients in K/DOQI
CKD Stages III to V had anemia. Anemia in patients
with CKD may predispose to ischemic heart disease,
heart failure and premature death [22,34]. Previous stu-
dies reported an increased risk of death among anemic
patients with or without renal impairment [35]. In our
study, among stroke patients with anemia, the hospital
and one-year mortality rates increased with a decreasing
hemoglobin.
There are different reasons why anemia and chronic
kidney disease could be risk factors for mortality:
chronic anemia involves hemodynamic compensations,
for example an increase in heart rate, cardiac index and
stroke work, as well as an amplification of hypoxia.
These compensations stress the ventricular function and
worsen the dysfunction among patients with heart fail-
ure and, thus, could consequently increase the risk of
death [36]. Anemia is associated with changes in left
ventricular anatomy among patients with CKD [37], a
change that could also increase death rates. Further-
more, reduced hemoglobin may be associated with other
risk factors of cardio-vascular mortality [29] and it may
result in worsening ischemia by amplifying hypoxia [37].
Several studies have demonstrated that the level of
Table 4 Results of Cox Proportional Hazard Model for One-Year Mortality in Patients Hospitalized for a First Stroke,
CHUV, 2001-2003, N = 856
Variables Parameter Estimate Standard Error Hazard Ratio (95% CI)
Hemoglobin (g/L, continuous) - 0.0163 0.0056 0.98* (0.97-1.00)
Glomerular filtration rate (ml/min/1.73 m
2, continuous) - 0.0114 0.0073 0.99 (0.98-1.01)
Age (years, continuous) 0.0398 0.0113 1.04* (1.02-1.07)
Hypertension - 0.3911 0.2359 0.68 (0.43-1.07)
Hypercholesterolemia - 0.4503 0.2728 0.64 (0.37-1.09)
Previous transitory ischemic attack - 1.1605 0.7230 0.31 (0.08-1.29)
Functional status II (ref = I) 0.5474 0.5196 1.73 (0.62-4.79)
Functional status III (ref = I) 0.9331 0.5008 2.54 (0.95-6.79)
Functional status IV (ref = I) 1.8335 0.4471 6.26* (2.61-15.02)
Charlson comorbidity index 2 (ref = 0 or I) 0.4103 0.4564 1.51 (0.62-3.69)
Charlson comorbidity index 3 (ref = 0 or I) 0.0646 0.3743 1.07 (0.51-2.22)
Charlson comorbidity index 4 (ref = 0 or I) 0.6228 0.3662 1.86 (0.91-3.82)
*p < 0.05.
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mortality in patients with heart failure and hypothesized
several explanations [29]. For example, reduced kidney
function may be associated with other risk factors for
mortality. In addition, kidney disease may be a risk fac-
tor for the progression of cardiac dysfunction by wor-
sening fluid and sodium retention, thus fostering left
ventricular dilatation and hypertrophy, a strong predic-
tor of stroke risk [38]. Furthermore CKD may induce
other pathophysiologic processes that may increase
stroke risk, like inducing oxidative stress, which could
promote atherosclerosis. These elements may contribute
to cerebral ischemia and increase the risk of ischemic
stroke [39]. Moreover, risk factors for stroke, such as
diabetes, hypertension or cardiovascular diseases are
more common among dialysis patients [6] and uremia
causes accelerated atherosclerotic vascular disease. One
study showed that increased aortic stiffness among CKD
patients was an explanation why CKD is a predictor of
cardio- and cerebrovascular mortality [40,41].
Most patients with ESRD and even less severe kidney
dysfunction are anemic because of a deficient erythro-
poietin production. Erythropoietin was shown to have
neuronal protective effects in animal models of ische-
mia-induced stroke and brain injury [42]. When renal
function is reduced, erythropoietin production is
impaired, which could limit erythropoietin-induced neu-
ronal protection against anemia-induced stroke. Thus,
the combination of anemia and CKD could interact to
make a stroke event more likely to occur or more likely
to be clinically severe [6]. Furthermore, it was shown
that hemodialysis patients have better outcomes than
patients suffering from renal insufficiency but getting no
treatment. However, patients on continuous ambulatory
peritoneal dialysis have a greater risk of stroke than the
general population. This is explainable by a poor control
of hypertension, which is presumably partly due to over-
hydration in patients getting peritoneal dialysis [43].
This study has several limitations. First, it included
only patients with first-ever clinical stroke, and therefore
did not reflect the impact of CKD and anemia on all
patients suffering from stroke. However, compared with
all patients suffering from stroke, our cohort represents
a more homogenous population, with younger patients
in which secondary prevention and treatment may have
higher impact. Second, we had no information on the
duration of CKD or anemia. We did not know the cause
of anemia for all patients. For some patients, anemia
could be linked to CKD. There could be other causes of
anemia like folate, iron, vitamin B12 deficiency, gastro-
intestinal diseases, -bleeding, cancer or chronic inflam-
matory illness. Third, we did not know the cause of
death of the stroke patients. We did not know whether
they died from complications of their stroke or from
another cause. Fourth, we took all the laboratory values
from the first day of admission to hospital. Maybe these
values were wrongly elevated in patients who arrived in
the hospital in a dehydrated situation. Finally, we may
question the study’s external validity because it was con-
ducted in an academic medical centre. However, this
centre is also the principal referral centre for the region
from which most patients were referred.
Conclusion
This study has confirmed the deleterious effect of renal
deficiency and anemia on survival in patients who sus-
t a i n e daf i r s ts t r o k e .W eh a v es h o w nt h a ta n e m i ai s
independently associated with a lower one-year survival.
Thus, it might be useful to treat patients with kidney
disease and anemia as early as possible in order to
reduce the complications and co-morbidities that result
from these diseases. Indeed, CKD is very often under
diagnosed and under-treated [12]. Appropriate trials
should be conducted to examine if early interventions to
detect and treat systematically renal insufficiency and
anemia in patients experiencing a first stroke may
improve survival and qualityo fl i f e .H o w e v e r ,t h es o l u -
tion may not be easy. Indeed, a trial of darbepoetin alfa
in patients with type 2 diabetes and chronic kidney dis-
ease, not undergoing dialysis, (TREAT study) has indi-
cated an increased risk of stroke [43].
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